Novartis iptacopan meets primary endpoint in new rare kidney disease trial
PharmiWeb,
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant…
Novartis Investigational Atrasentan Phase III Study Demonstrates Clinically Meaningful and Highly Statistically Significant Proteinuria Reduction in Patients with IgA Nephropathy (IgAN)
Drugs.com,
Phase III ALIGN study met its primary endpoint, demonstrating superiority of atrasentan vs.
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Biz Wire Express,
GlobeNewswire 2023-10-30 Ad hoc announcement pursuant to Art. 53 LR Basel, October 30, 2023 — Novartis today announced positive…
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Finanzen,
Ad hoc announcement pursuant to Art. 53 LR Phase III ALIGN study met its primary endpoint, demonstrating superiority of…